
Opinion|Videos|November 12, 2024
Sequencing and Combination Strategies with Pirtobrutinib and CAR-T Therapy in R/R CLL
Author(s)Nitin Jain, MD, Joanna M. Rhodes, MD, MSCE
Panelists discuss how they approach treatment selection for multi-refractory chronic lymphocytic leukemia (CLL) patients, considering factors such as prior therapy responses, patient fitness, and disease characteristics to guide choices among available options, including CAR T-cell therapy, while also addressing the limitations and challenges associated with each treatment modality in their decision-making process.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Which treatment options do you offer to your multi-refractory CLL patients and how do you select among available therapies?
- What key factors guide your decision to use CAR T-cell therapy in the R/R setting and what criteria do you use to select patients for this treatment?
- What are some limitations or challenges associated with these therapies and how do you weigh these into your
Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
3
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
4
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
5

